NCT07861685Recruiting
Role of Postpartum Furosemide in Recovery of Patients With Severe Preeclampsia
Efficacy of Postpartum Furosemide in Patients With Severe Preeclampsia: A Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 6 Oct 2026
Brief summary (registry, in English)
This randomized controlled trial will compare oral furosemide with placebo for improving blood pressure control in women with severe preeclampsia after delivery. Participants will receive either 20 mg of furosemide or a placebo tablet once daily for 5 days, in addition to standard postpartum treatment for high blood pressure. Blood pressure, symptoms, adverse events, and the need for additional antihypertensive medication will be monitored for 7 days after delivery. The study will assess whether adding furosemide helps achieve better postpartum blood pressure control compared with placebo.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 434 (estimated)
- First submitted
- 1 Oct 2026
- Start date
- 1 Oct 2026
- Primary completion date
- 15 Mar 2027
- Lead sponsor
- Lady Reading Hospital, Pakistan
- Diseases
- High blood pressure
- NCT number
- NCT07861685
What you commit to
- Study type: Interventional
- Planned participants: 434
- From 1 Oct 2026 to the primary completion date, 15 Mar 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of allergy to furosemide or prior use of diuretics before randomization
Other illness
- History of underlying cardiac disease during pregnancy or postpartum
- Known rheumatologic disease or advanced diabetes
- History of thyroid disorders or other medical illnesses that may interfere with blood pressure management
Lab values
- Pre-existing renal dysfunction or serum creatinine \>1.2 mg/dL on medical record
Other
- Significant hypokalemia (K \<3 mEq/L) before enrollment
Who the study is looking for
- Women aged 18 to 45 years
- Any parity
- Gestational age \>28 weeks based on LMP
- Severe preeclampsia as per the study operational definition
Age in the registry: 18 years to 45 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Lady Reading Hospital Coordinator of this site? Confirm its status | Peshawar | Pakistan | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.